9:38 AM
 | 
Jan 05, 2018
 |  BC Week In Review  |  Clinical News  |  Regulatory

Agile gets second CRL for Twirla

Agile Therapeutics Inc. (NASDAQ:AGRX) said on Dec. 22, 2017, that FDA issued a second complete response letter for Twirla (AG200-15), a once-weekly transdermal contraceptive patch....

Read the full 101 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >